Genmab A/s
About
Genmab A/s (NASDAQ:GMAB) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 14 2026
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Apr 13 2026
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Mar 19 2026
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
Mar 2 2026
Correction to Company Announcement No. 13 of March 2, 2026
Feb 25 2026
Genmab to Participate in Upcoming Investor Conferences
Financials
Revenue
$3.72 B
Market Cap
$16.98 B
P/E Ratio
17.86
EPS
1.54